How are the Premier's Awards helping cancer researchers?
2 May 2019
The Premier’s Awards not only recognise the state’s top cancer researchers but also propels their work to greater heights.
Hear from the 2017 winners and find out how it is influencing their work:
Melanoma Translational Research Team
– Wildfire Highly Cited Publication Award
The award is allowing Professor Rizos’ team to extend their research into regulating melanoma gene expression and its role in the response of melanoma to immunotherapy.
Melanoma Institute Australia
– Excellence in Translational Cancer Research Award
The award is supporting a plethora of Melanoma Institute Australia research projects that made headlines around the world. These include discovering the specific mechanisms behind immune-mediated equilibrium
Professor Scolyer and Professor Long won major awards at the 2018
– Outstanding Cancer Researcher of the Year Award
Professor Kefford’s is commissioning a tailor-made, melanoma-specific gene mutation panel for DNA sequencing machinery in their laboratory. The award is enabling his team to extend their research into regulating melanoma gene expression and its role in the response of melanoma to immunotherapy.
"International collaboration remains the key to ensuring this pioneering research continues so we can increase survival rates for advanced melanoma patients and move us closer to achieving our goal of zero deaths from melanoma," says Professor Georgina Long, of the clinical trial results presented at ESMO 2018.
Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.
A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.
The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.
The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
When David lost his life last year, he was 33, with three daughters under six.
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.
Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology.
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.
An American study has discovered a link between early detection and marital status in melanoma diagnosis.
An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.